BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 2015;11:811-21. [PMID: 25800061 DOI: 10.1517/17425255.2015.1027684] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol 2020;21:27. [PMID: 32266582 DOI: 10.1007/s11864-020-0719-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
2 Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 2019;19:556-563. [PMID: 30723313 DOI: 10.1038/s41397-019-0077-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
3 Lampropoulou DI, Laschos K, Amylidi AL, Angelaki A, Soupos N, Boumpoucheropoulos S, Papadopoulou E, Nanou E, Zidianakis V, Nasioulas G, Fildissis G, Aravantinos G. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? J Oncol Pharm Pract. 2020;26:747-753. [PMID: 31382864 DOI: 10.1177/1078155219865597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zurayk M, Keung Y, Yu D, Hu EH. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. J Oncol Pharm Pract 2019;25:234-8. [DOI: 10.1177/1078155217732141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
5 Liu XY, Zhang FR, Shang JY, Liu YY, Lv XF, Yuan JN, Zhang TT, Li K, Lin XC, Liu X, Lei Q, Fu XD, Zhou JG, Liang SJ. Renal inhibition of miR-181a ameliorates 5-fluorouracil-induced mesangial cell apoptosis and nephrotoxicity. Cell Death Dis 2018;9:610. [PMID: 29795190 DOI: 10.1038/s41419-018-0677-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
6 Grobárová V, Vališ K, Talacko P, Pavlů B, Hernychová L, Nováková J, Stodůlková E, Flieger M, Novák P, Černý J. Quambalarine B, a Secondary Metabolite from Quambalaria cyanescens with Potential Anticancer Properties. J Nat Prod 2016;79:2304-14. [PMID: 27571379 DOI: 10.1021/acs.jnatprod.6b00362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Duan T, Xu Z, Sun F, Wang Y, Zhang J, Luo C, Wang M. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation. Biomed Pharmacother 2019;117:109121. [PMID: 31252265 DOI: 10.1016/j.biopha.2019.109121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
8 Hishinuma E, Gutiérrez Rico E, Hiratsuka M. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. J Clin Med 2020;9:E2342. [PMID: 32707991 DOI: 10.3390/jcm9082342] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Syn NL, Yong WP, Lee SC, Goh BC. Genetic factors affecting drug disposition in Asian cancer patients. Expert Opin Drug Metab Toxicol 2015;11:1879-92. [PMID: 26548636 DOI: 10.1517/17425255.2015.1108964] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Peters GJ, Honeywell RJ. Drug transport and metabolism of novel anticancer drugs. Expert Opin Drug Metab Toxicol 2015;11:661-3. [PMID: 25940025 DOI: 10.1517/17425255.2015.1041255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Chong JH, Ghosh AK. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.Interv Cardiol. 2019;14:89-94. [PMID: 31178935 DOI: 10.15420/icr.2019.12] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
12 Saba NF, Mody MD, Tan ES, Gill HS, Rinaldo A, Takes RP, Strojan P, Hartl DM, Vermorken JB, Haigentz M Jr, Ferlito A. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. Crit Rev Oncol Hematol 2017;115:50-8. [PMID: 28602169 DOI: 10.1016/j.critrevonc.2017.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
13 Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, Dixon K, Fan K, Bowlby R, Jones MR, Shen Y, Grewal JK, Ashkani J, Wee K, Grisdale CJ, Thibodeau ML, Bozoky Z, Pearson H, Majounie E, Vira T, Shenwai R, Mungall KL, Chuah E, Davies A, Warren M, Reisle C, Bonakdar M, Taylor GA, Csizmok V, Chan SK, Zong Z, Bilobram S, Muhammadzadeh A, D’souza D, Corbett RD, Macmillan D, Carreira M, Choo C, Bleile D, Sadeghi S, Zhang W, Wong T, Cheng D, Brown SD, Holt RA, Moore RA, Mungall AJ, Zhao Y, Nelson J, Fok A, Ma Y, Lee MKC, Lavoie J, Mendis S, Karasinska JM, Deol B, Fisic A, Schaeffer DF, Yip S, Schrader K, Regier DA, Weymann D, Chia S, Gelmon K, Tinker A, Sun S, Lim H, Renouf DJ, Laskin J, Jones SJM, Marra MA. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat Cancer 2020;1:452-68. [DOI: 10.1038/s43018-020-0050-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 24.0] [Reference Citation Analysis]
14 Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome. Chem Res Toxicol 2016;29:1591-601. [DOI: 10.1021/acs.chemrestox.6b00215] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
15 Yu X, Hou J, Shi Y, Su C, Zhao L. Preparation and characterization of novel chitosan-protamine nanoparticles for nucleus-targeted anticancer drug delivery. Int J Nanomedicine 2016;11:6035-46. [PMID: 27881917 DOI: 10.2147/IJN.S117066] [Cited by in Crossref: 15] [Article Influence: 3.0] [Reference Citation Analysis]
16 Campbell JM, Bateman E, Peters MD, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 2016;17:435-51. [DOI: 10.2217/pgs.15.180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
17 Duran G, Cruz R, Simoes AR, Barros F, Giráldez JM, Bernárdez B, Anido U, Candamio S, López-López R, Carracedo Á, Lamas MJ. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics? J Chemother 2020;32:310-22. [PMID: 32441565 DOI: 10.1080/1120009X.2020.1764281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chao YL, Anders CK. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy. Clin Breast Cancer 2018;18:e301-4. [PMID: 28899623 DOI: 10.1016/j.clbc.2017.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. Br J Cancer 2018;118:1084-8. [PMID: 29523831 DOI: 10.1038/s41416-018-0005-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Deligonul A, Aksoy S, Tezcan G, Tunca B, Kanat O, Cubukcu E, Yilmazlar T, Ozturk E, Egeli U, Cecener G, Alemdar A, Evrensel T. DPYD c.1905 + 1G>A Promotes Fluoropyrimidine-Induced Anemia, a Prognostic Factor in Disease-Free Survival, in Colorectal Cancer. Genet Test Mol Biomarkers 2021;25:276-83. [PMID: 33877893 DOI: 10.1089/gtmb.2020.0285] [Reference Citation Analysis]
21 Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomedicine 2017;12:1305-15. [PMID: 28243091 DOI: 10.2147/IJN.S123742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
22 Hamzic S, Kummer D, Froehlich TK, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens JH, García-gonzález X, López-fernández LA, Amstutz U, Largiadèr CR. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological Research 2020;152:104594. [DOI: 10.1016/j.phrs.2019.104594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
23 Klimko A, Tieranu CG, Olteanu AO, Preda CM, Ionescu EM. Capecitabine-Induced Terminal Ileitis: Case Report and Literature Review. Cureus 2021;13:e14621. [PMID: 34055501 DOI: 10.7759/cureus.14621] [Reference Citation Analysis]
24 Qingwei Z, Dongsheng H, Duo L, Youlei W, Songxia Y, Ziqi Y, Lanjuan L. Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients. Front Oncol 2020;10:1542. [PMID: 32984012 DOI: 10.3389/fonc.2020.01542] [Reference Citation Analysis]
25 Macaire P, Morawska K, Vincent J, Quipourt V, Marilier S, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A. Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. Eur J Cancer 2019;111:116-25. [PMID: 30849685 DOI: 10.1016/j.ejca.2019.01.102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Sudha T, Bharali DJ, Yalcin M, Darwish NH, Coskun MD, Keating KA, Lin H, Davis PJ, Mousa SA. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomedicine 2017;12:195-205. [DOI: 10.2217/nnm-2016-0315] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
27 Desai A, Mohammed T, Patel KN, Almnajam M, Kim AS. 5-Fluorouracil Rechallenge After Cardiotoxicity. Am J Case Rep 2020;21:e924446. [PMID: 32860674 DOI: 10.12659/AJCR.924446] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ratti M, Hahne JC, Toppo L, Castelli E, Petrelli F, Passalacqua R, Barni S, Tomasello G, Ghidini M. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol 2019;11:1758835919853954. [PMID: 31210799 DOI: 10.1177/1758835919853954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Florczak A, Grzechowiak I, Deptuch T, Kucharczyk K, Kaminska A, Dams-Kozlowska H. Silk Particles as Carriers of Therapeutic Molecules for Cancer Treatment. Materials (Basel) 2020;13:E4946. [PMID: 33158060 DOI: 10.3390/ma13214946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]